Current Medical Science最新文献

{"title":"Peptide Loading Complex in Cancer: From Peptide Translocation, Editing, and Loading into MHC-I to a Potential Therapeutic Target.","authors":"Omer Qutaiba B Allela, Abdulkareem Shareef, Hayder Naji Sameer, Ahmed Yaseen, Zainab H Athab, Mohaned Adil","doi":"10.1007/s11596-026-00227-3","DOIUrl":"10.1007/s11596-026-00227-3","url":null,"abstract":"<p><p>The peptide-loading complex (PLC) is a pivotal endoplasmic reticulum (ER) protein machinery that facilitates peptide translocation, editing, and loading onto major histocompatibility complex class I (MHC-I) to allow recognition of infected or transformed cells by CD8⁺ cytotoxic T lymphocytes (CTLs). PLC comprises the peptide transporter complex formed of transporters associated with antigen processing (TAP1/2), the adapter protein tapasin, chaperones such as calreticulin (CRT) and ERp57, and β2-microglobulin (β2M), ensuring the proper assembly of MHC-I/peptide complexes for subsequent antigen presentation on the cell surface. In cancer, tumorigenesis often involves structural malfunctions and transcriptional, post-transcriptional, and epigenetic modifications that impair the functioning of PLC proteins. This eventually causes loss of MHC-I cell-surface expression, failure of antigen presentation, and escape from CTL-mediated immunosurveillance. Although malfunctions in antigen-processing machineries are well known, herein we provide an overview of the PLC as a major determinant of tumor immune escape and a potential therapy target. In this regard, recent evidence indicates that individual PLC components not only affect MHC-I/antigen presentation but also influence tumor development and progression, immune evasion, and treatment resistance. Furthermore, we explore existing or evolving therapeutic approaches to recover/reprogram PLC functions such as IFN-γ-induced PLC activation, TAP1 and tapasin gene therapy, epigenetics-based treatments such as DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi), and microRNA targeting strategy.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":"926-945"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Burden of Peptic Ulcer Disease (1990-2021) and Projections to 2050: A Comprehensive Analysis of Age, Sex, and Socioeconomic Disparities.","authors":"Jing Gong, Ke Zhang, Jun-Wei Yan, Xiao-Xia Zhang, Jing Liu","doi":"10.1007/s11596-026-00215-7","DOIUrl":"10.1007/s11596-026-00215-7","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Peptic ulcer disease (PUD) represents an ongoing global public health concern and is responsible for significant illness and mortality. Despite considerable advancements in medical therapy, the distribution and overall burden of PUD vary substantially across different regions and population segments worldwide. This research provides a comprehensive analysis of the global PUD burden, examining trends from 1990 to 2021 and forecasting patterns until 2050. The findings of this research, which use the most up-to-date epidemiological data available, are significant for epidemiology and disease management.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We leveraged data from the Global Burden of Disease (GBD) 2021 study, which covers 195 countries and territories. Our analysis assessed key metrics of disease impact, including disability-adjusted life years (DALYs), mortality rates, incidence and prevalence data, years lived with disability (YLDs), and years of life lost (YLLs). We calculated age-standardized rates (ASRs) to allow for consistent comparisons across populations. Temporal changes were quantified using estimated annual percentage changes (EAPCs) derived from linear regression. Furthermore, we applied hierarchical cluster analysis to investigate regional patterns in the PUD burden. These methods were chosen because of their robustness and ability to provide a comprehensive understanding of the global burden of PUD.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;PUD was responsible for an estimated 6.06 million DALYs in 2021 (ASR: 71.56 per 100,000). This burden increased substantially with advancing age, peaking among individuals aged 80 and above. Compared with females, males had higher DALY rates (ASR: 87.02 vs 57.05 per 100,000) and considerably higher mortality rates. Regions with low and low-middle sociodemographic index (SDI) presented the highest ASRs (e.g., 178.38 per 100,000 in low-SDI areas). The highest DALY rates were observed in South Asia and parts of sub-Saharan Africa. Between 1990 and 2021, the global DALY ASR decreased markedly (EAPC: -2.96), though absolute DALY numbers remained elevated in populous, low- to middle-SDI regions. Model-based projections (exponential smoothing and ARIMA), assuming the continuation of recent trends, suggest that ASRs may continue to decline through 2050.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Over the past three decades, the global age-standardized burden of PUD has markedly decreased. However, significant challenges remain, particularly for older adults, males, and individuals in low-SDI areas, such as South Asia and sub-Saharan Africa. Although forecasts suggest further reductions in ASRs, the overall burden, influenced by population changes, underscores the crucial need for ongoing, targeted prevention and control efforts. This should prioritize Helicobacter pylori detection and eradication, safer NSAID use with gastroprotection in high-risk patients, and improved access to timely diagnosis ","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":"1023-1037"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148270312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcoming the Viscosity-Strength Trade-Off in 3D-Printable Dental Resins by Hydrogen Bond Engineering.","authors":"Yu-Lin Hou, Fei-Long Wang, Hui-Yu Shang, Dong Xiang, Yu-Fei Wang, Li Gao, Fei-Yan Yu, Yong-Xiang Xu","doi":"10.1007/s11596-026-00221-9","DOIUrl":"10.1007/s11596-026-00221-9","url":null,"abstract":"<p><strong>Objective: </strong>To overcome the trade-off between the low viscosity required for printability and the high mechanical strength required for functionality in dental resins for vat photopolymerization 3D printing by developing a hydrogen-bond engineering strategy.</p><p><strong>Methods: </strong>Three dental oligomers (Bis-GMA, UDMA, and Bis-EMA) were blended with four diluents differing in hydrogen-bonding ability. Fourier transform infrared (FTIR) spectroscopy, rheometry, three-point bending tests and 3D printing performance tests were carried out to evaluate hydrogen bond formation, viscosity, mechanical properties, printability and accuracy.</p><p><strong>Results: </strong>FTIR and rheological tests confirmed strong hydrogen bonding between MAA and matrix oligomers. The optimized formulation, n(MAA): n(UDMA) = 2:1, achieved flexural strengths of 228 MPa (mold-filled) and 178 MPa (3D-printed) and elastic modulus of 5.3 GPa and 4.0 GPa, respectively, whereas the viscosity was only 307 mPa·s-a dramatic improvement over that of neat UDMA (viscosity 9689 mPa·s, mold-filled mechanical strength 174 MPa and 3.8 GPa). The hydrogen-bonding diluents also demonstrated significant advantages in composite resin formulations.</p><p><strong>Conclusions: </strong>Hydrogen bond engineering decouples viscosity from mechanical strength, enabling the fabrication of low-viscosity, high-strength dental resins for 3D printing. This scalable platform overcomes the longstanding viscosity-strength trade-off, offering promising potential for dentistry and other fields of photocurable additive manufacturing.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":"1072-1088"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing and Location are Keys: ERCP Success and Its Benefit in MPD Injury after Acute Pancreatitis.","authors":"Zhi-Jun Suo, Xiao-Jia Xiao, Bo Ye, Zhi-Hui Tong, Wei-Qin Li","doi":"10.1007/s11596-026-00224-6","DOIUrl":"10.1007/s11596-026-00224-6","url":null,"abstract":"<p><strong>Objective: </strong>Transpapillary therapy remains a critical treatment modality for main pancreatic duct (MPD) injury after acute necrotizing pancreatitis. This study aimed to verify the factors linked to the technical success of transpapillary drainage by endoscopic retrograde cholangiopancreatography (ERCP) in managing MPD injury, and the impact of technical success on tube duration and overall survival.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on patients who underwent ERCP for MPD injuries following acute pancreatitis from May 2019 to April 2021. Univariate and multivariate logistic regression analyses were employed to identify factors associated with successful treatment. Kaplan-Meier curves were used to analyze the impact of technical success on tube duration and overall survival.</p><p><strong>Results: </strong>We included 63 patients in whom MPD opacification was achieved (43 technical successes and 20 failures). The technical success group had a significantly higher proportion of patients whose interval from onset of acute pancreatitis to endoscopic transpapillary drainage (IOP) was less than 90 days (58.14%) than the failure group (20.00%, P = 0.005). Multivariate analysis revealed that an IOP < 90 days (OR = 0.24, 95% CI: 0.06-0.91, P = 0.036) and MPD injury located outside the head and neck of the pancreas (OR = 4.66, 95% CI: 1.10-19.77, P = 0.036) were independently associated with technical success. Technical success was associated with a shorter median tube indwelling time (10.3 months, 95% CI: 7.3-13.3) compared to technical failure (16.8 months, 95% CI: 12.3-21.3, P = 0.025).</p><p><strong>Conclusions: </strong>ERCP should be performed within 90 days in patients with MPD injury, and the procedure has a higher success rate when the injury occurs outside the head and neck of the pancreas. This technical success significantly shortens drainage tube indwelling time and improves patients' quality of life.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":"1038-1045"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148351021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Matrix Competence Failure in Osteoporosis: Mechanosensing, Osteoimmune Crosstalk, and Fragility Beyond Bone Mineral Density.","authors":"Tian-Ge Xia, Yi-Jie Zhang, Shao-Shuo Li, Yi Zhou, Wen-Yu Tian, Zhi-Wei Jiang, Yang Shao, Jian-Wei Wang","doi":"10.1007/s11596-026-00235-3","DOIUrl":"10.1007/s11596-026-00235-3","url":null,"abstract":"<p><p>Osteoporosis is typically characterized by reduced bone mass and deterioration of microarchitecture. However, bone mineral density (BMD) does not fully account for the wide variations in skeletal fragility. In this study, we propose that matrix competence is the capacity of the mineralized extracellular matrix (ECM), the lacunar-canalicular network (LCN), and the osteocyte network to ensure material integrity, maintain network connectivity, and present appropriate cell-matrix adhesion cues. When these properties are degraded, matrix-to-signal breakdown occurs: mechanical and inflammatory inputs are no longer translated efficiently into coordinated remodeling. Research findings on bone material biology, osteocyte regulation, mechanotransduction, and osteoimmunology indicate that load-adaptive formation requires efficient signal amplification and propagation across matrix and cellular networks. During aging and unloading, the properties of collagen-mineral material decrease, LCN and osteocyte coupling decrease, and anabolic adaptation becomes blunted. Chronic low-grade inflammation and immune remodeling can further exploit altered ECM positioning and adhesion, reinforcing resorptive remodeling. We suggest that reduced matrix competence provides a tissue-level explanation for the relationships among BMD, fracture risk, and therapeutic response. This framework places matrix material properties, network structural integrity, and remodeling coordination at the center of osteoporosis phenotyping independent of BMD.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":"970-982"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Endoplasmic Reticulum Stress-Related Gene Signature in Thyroid Cancer.","authors":"Min Wang, Xiao-Peng Guo, Zi-Bo Yuan, Ya-Wen Guo, Guo-Wan Zheng, Rui-Min Liang, Jie Ma, Jia-Qi Wang, Xiao-Gang Wang, Fa-Huan Song, Xin Zhu, Lu-Qiang Jin","doi":"10.1007/s11596-026-00223-7","DOIUrl":"10.1007/s11596-026-00223-7","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the contribution of endoplasmic reticulum (ER) stress to the progression of thyroid cancer (TC) and to construct a prognostic gene signature.</p><p><strong>Methods: </strong>Differential expression analysis was performed on 572 samples from The Cancer Genome Atlas (TCGA). ER stress-related genes (ERSGs) were obtained from the GeneCards database. Overlap analysis revealed 178 differentially expressed ERSGs. Least absolute shrinkage and selection operator (LASSO) regression and multivariate Cox regression were used to construct a prognostic risk model. The model was validated in a test set (n = 172) and an independent clinical cohort (n = 90) by RT-qPCR. Immune infiltration, immune checkpoint expression, and drug sensitivity were compared between the high- and low-risk groups using the CIBERSORT algorithm and the Genomics of Drug Sensitivity in Cancer (GDSC) database.</p><p><strong>Results: </strong>A total of 5,253 differentially expressed genes and 518 ERSGs were identified, yielding 178 overlapping genes. An 11-gene prognostic model (CDKN1A, HTR2A, ATF3, MTTP, BRSK2, EGF, CASP12, HSPA5, IL1A, FOXRED2, CASQ2) was constructed. Patients in the high-risk group had significantly worse overall survival than those in the low-risk group did (log-rank P < 0.001; hazard ratio [HR] = 2.34; 95% CI: 1.58-3.47). The model showed good predictive performance, with AUC values of 0.74, 0.72, and 0.71 for 1-, 3-, and 5-year overall survival, respectively. Significant differences in tumor immune cell infiltration (e.g., Tregs, P < 0.01; M2 macrophages, P < 0.05) and drug sensitivity (e.g., gefitinib, P < 0.05) were detected between the two groups. In 90 clinical samples, the expression patterns of the 11 genes were validated by RT-qPCR (all P < 0.05), which was consistent with the bioinformatics findings.</p><p><strong>Conclusion: </strong>The 11-gene ER stress-related signature independently predicted prognosis in patients with TC across both the TCGA cohort and an independent cohort. This study provides new insight into the role of ER stress in TC and may facilitate the identification of prognostic biomarkers and support clinical decision-making.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":"1099-1114"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances and Clinical Applications of Thrombopoietic Agents.","authors":"Jin-Huan Xu, Yu-Ting Gong, Yi-Cheng Zhang, Jia Wei, Li-Jun Jiang","doi":"10.1007/s11596-026-00218-4","DOIUrl":"10.1007/s11596-026-00218-4","url":null,"abstract":"<p><p>Thrombocytopenia remains a formidable clinical challenge across a broad spectrum of medical conditions, as it substantially elevates hemorrhagic risk and complicates established therapeutic protocols. Although platelet transfusions have traditionally served as the cornerstone of management, their utility is frequently constrained by transient efficacy and inherent logistical burdens. The emergence of thrombopoietic agents, particularly second-generation thrombopoietin receptor agonists (TPO-RAs), has shifted the treatment landscape by offering a more direct and targeted way to stimulate platelet production. This review evaluates the mechanisms and clinical utility of contemporary therapies, spanning from recombinant human thrombopoietin (rhTPO) and established TPO-RAs (eltrombopag, romiplostim, and herombopag) to emerging classes such as spleen tyrosine kinase (SYK) and Bruton tyrosine kinase (BTK) inhibitors. We delineate their specific roles in the management of immune thrombocytopenia (ITP), chemotherapy-induced thrombocytopenia (CIT), chronic liver disease (CLD), and aplastic anemia (AA). Despite these advancements, challenges including inconsistent response rates, long-term safety considerations, and accessibility barriers persist. Looking ahead, the field is pivoting toward personalized management strategies and next-generation agents to further refine patient care and optimize clinical outcomes.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":"867-880"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine Learning-Based Prediction of Mononuclear Cell Collection Efficiency for CAR-T Manufacturing.","authors":"Wei Xie, Lin Liu, Jin-Hui Shu, Meng-Yi Du, Heng Mei","doi":"10.1007/s11596-026-00237-1","DOIUrl":"10.1007/s11596-026-00237-1","url":null,"abstract":"<p><strong>Objective: </strong>To develop and internally validate an interpretable machine-learning model using routine precollection variables to predict mononuclear cell (MNC) collection efficiency (CE) during leukapheresis for CAR-T manufacturing.</p><p><strong>Methods: </strong>This retrospective study included 206 consecutive patients who underwent leukapheresis between 2022 and 2025. Candidate variables were screened with Pearson correlation, Boruta, recursive feature elimination, and variance-threshold filters. Six supervised algorithms were trained with nested cross-validation, using an inner fivefold loop for tuning and an outer tenfold loop repeated three times for performance estimation. Bootstrap resampling (1000 iterations) generated confidence intervals, and SHAP analysis was used for interpretation.</p><p><strong>Results: </strong>Extreme gradient boosting (XGBoost) showed the best continuous prediction performance, with an R² of 0.67 (95% CI: 0.64-0.70), Pearson r = 0.82, RMSE = 12.4%, and MAE = 9.8%. In the secondary triage analysis, observed high CE was defined as CE ≥ 60% (33/206, 16.0%). The predicted CE score discriminated high CE with an AUC of 0.84. A predicted-CE threshold of ≥ 50% yielded sensitivity of 84.8%, specificity of 97.1%, PPV of 84.8%, and NPV of 97.1%. The leading predictors were precollection lymphocyte count, lymphocyte/WBC ratio, age, body surface area, and monocyte count.</p><p><strong>Conclusion: </strong>Routine precollection variables estimated MNC CE with good internal validity and may support individualized leukapheresis planning before CAR-T manufacturing.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":"1014-1022"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13503503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone Morphogenetic Proteins in Obesity Management: Therapeutic Potential and Challenges Beyond the Skeleton.","authors":"Jing Zhang, Nan Jiang, Li-Juan Wang, Ting-Bing Cao, Yang-Li Xie, Li Li","doi":"10.1007/s11596-026-00222-8","DOIUrl":"10.1007/s11596-026-00222-8","url":null,"abstract":"<p><p>Bone morphogenetic proteins (BMPs) are bone-derived osteokines that regulate energy metabolism and combat obesity by promoting brown adipocyte differentiation. BMP4, BMP7, BMP8B, and BMP9 are highly expressed in osteoblasts and bone matrix, from which they are released into circulation. They act as endocrine factors that induce brown adipogenesis, increase mitochondrial biogenesis, and increase thermogenesis via conserved signaling pathways (Smad, MAPK, and PGC1α). Concurrently, these BMPs maintain skeletal homeostasis and mediate crosstalk between bone and metabolic organs, including adipose tissue and the hypothalamus, thereby regulating appetite and energy balance. Preclinical studies have confirmed that BMP-based interventions can increase energy expenditure, improve insulin sensitivity, and alleviate obesity-related complications. However, clinical translation remains hindered by adverse effects, short half-lives, and obesity-induced BMP resistance. This review first elucidates the peripheral and central regulatory mechanisms of BMPs in energy metabolism, clarifies the subtype-specific metabolic effects of major BMPs, further evaluates their therapeutic potential against obesity and metabolic syndrome, and finally analyzes the core obstacles to clinical implementation and corresponding solution strategies.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":"899-913"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148270610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 3D PDMS Scaffold Microchip Platform for Non-Invasive Detection of Circulating Endometrial Cells: Revolutionizing Endometriosis Diagnosis.","authors":"Shu-Hao Yang, Yi-Ke Wang, Li-Li Xu, Fei Liu, Qing Yan, Fan-Ke Huang, Su-Zhen Yuan, Wei Yan, Hai-Yi Liu, Min Xie, Wen-Wen Wang","doi":"10.1007/s11596-026-00233-5","DOIUrl":"10.1007/s11596-026-00233-5","url":null,"abstract":"<p><strong>Objective: </strong>To address the urgent need for non-invasive diagnosis of  endometriosis, this study developed a novel microfluidic platform utilizing a three-dimensional (3D) polydimethylsiloxane scaffold microchip to efficiently capture circulating endometrial cells (CECs).</p><p><strong>Methods: </strong>A prospective single-center study was performed from June 2022 to June 2023. Presurgical peripheral blood was collected from 42 patients with endometriosis and 20 controls. Microchips were functionalized with antibodies against epithelial cellular adhesion molecule (EpCAM) and cluster of differentiation 10 (CD10). They were used to capture and identify CECs for diagnostic evaluation.</p><p><strong>Results: </strong>The presence of CD10 was observed in 88.10% of cases (37/42), significantly higher than in controls (35%, 7/20, P < 0.001). Similarly, the levels of EpCAM were detected in 52.38% of cases (22/42) and 30% of controls (6/20, P = 0.25). In preoperative diagnosis, integrating CECs with clinical parameters achieved superior accuracy (AUC = 0.870) compared to CA125 (AUC = 0.813) and clinical-only models (AUC = 0.606-0.923). When comparing CEC levels before and after surgery, the CEC-integrated clinical model demonstrated robust diagnostic performance (AUC = 0.877).</p><p><strong>Conclusion: </strong>This 3D microfluidic platform enables precise, convenient, and non-invasive endometriosis identification via efficient CEC capture, offering significant potential for clinical translation.</p>","PeriodicalId":10820,"journal":{"name":"Current Medical Science","volume":" ","pages":"983-992"},"PeriodicalIF":2.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148618137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}